AI Image
Trump’s FDA pick faces Republican doubts as confirmation deadline nears
NBC News • • nation
Key Points:
- The FDA is expected to complete its safety review of the abortion pill mifepristone in March, but the agency may lack a permanent leader to oversee the decision as Dr. Heidi Overton's confirmation faces uncertainty.
- Overton, nominated by former President Trump, faces a Senate Health, Education, Labor and Pensions Committee vote next week, but key Republican senators remain undecided, complicating her path to confirmation before Democrats take control of the Senate on January 3.
- Senator Bill Cassidy, committee chairman, has expressed concerns about Overton's managerial experience and remains undecided after discussions with her, while Senators Susan Collins and Lisa Murkowski have not committed to supporting her nomination.
- Overton's record on abortion, including her past criticism of the FDA's allowance of mail delivery of mifepristone, has drawn scrutiny from Democrats, though she has stated she will not prejudge the ongoing safety review of the drug.
- The FDA has been without a permanent commissioner since May, and the next leader will face significant decisions on vaccines and abortion drug policies amid a politically charged environment.
